Los Angeles, CA (PRWEB) May 02, 2013
The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for those taking the medication Januvia. A recent study suggests the drug may have higher occurrence rates of pancreatitis and pancreatic cancer than traditional pills****.
DrugRisk was created to improve patient safety by providing the latest warnings, recalls, studies and legal news to those taking popular prescription drugs. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Januvia is a once-a-day pill introduced in 2006 to help those with type-2 diabetes control blood sugar. It has become Merck’s best-selling drug, with sales of over $4 billion last year*.
However, a 2011 study from UCLA indicated the drug could increase the risk of pancreatic cancer by 272% and thyroid cancer by 148%**. The Journal for the American Medical Association also recently warned Januvia could double the risk of pancreatitis, a major risk factor for pancreatic cancer***.
Now, DrugRisk has added a new study by the Institute for Safe Medication Practices, which found in an analysis of FDA reports that patients were 20.8 times as likely to report pancreatitis or pre-cancerous growth from Januvia than from traditional diabetes treatment like metformin****.
Due to the rising number of patients filing a Januvia lawsuit alleging cancer, lawyers have requested that cases be consolidated to a special federal multi-district court in California. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).
Anyone affected by cancer after taking Januvia is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Januvia lawsuits.
*Bloomberg News, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
**Gastroenterology, July, 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***Journal of the American Medical Association, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****Institute for Safe Medication Practices, 4/18/13; ismp.org/QuarterWatch/pdfs/2012Q3.pdf